Cargando…

2400. Activity of a Long-Acting Echinocandin, Rezafungin, Tested Against Invasive Fungal Isolates Collected Worldwide

BACKGROUND: Echinocandins are important agents for treating invasive fungal infections. We evaluated the activity of rezafungin (RZF; previously CD101), an echinocandin with extended half-life, and comparators using CLSI broth microdilution methods against 719 invasive fungal isolates collected worl...

Descripción completa

Detalles Bibliográficos
Autores principales: Pfaller, Michael A, Messer, Shawn A, Rhomberg, Paul R, Schaefer, Beth A, Castanheira, Mariana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253711/
http://dx.doi.org/10.1093/ofid/ofy210.2053
_version_ 1783373560017846272
author Pfaller, Michael A
Messer, Shawn A
Rhomberg, Paul R
Schaefer, Beth A
Castanheira, Mariana
author_facet Pfaller, Michael A
Messer, Shawn A
Rhomberg, Paul R
Schaefer, Beth A
Castanheira, Mariana
author_sort Pfaller, Michael A
collection PubMed
description BACKGROUND: Echinocandins are important agents for treating invasive fungal infections. We evaluated the activity of rezafungin (RZF; previously CD101), an echinocandin with extended half-life, and comparators using CLSI broth microdilution methods against 719 invasive fungal isolates collected worldwide during 2017. METHODS: Susceptibility tests were conducted on 616 Candida spp. (6 species), 25 C. neoformans (CNEO), 18 A. flavus (AFL), and 60 A. fumigatus (AFU) for RZF, anidulafungin, caspofungin, micafungin, and azoles. CLSI clinical breakpoint (CBP) and epidemiological cutoff value (ECV) interpretive criteria were applied. RESULTS: RZF inhibited 100.0% of C. albicans (CA) isolates, 96.3% of C. tropicalis (CT), 93.4% of C. glabrata (CG), 100.0% of C. krusei, and 100.0% of C. dubliniensis at ≤0.12 µg/mL. All but 2 (116/118 [98.3%]) C. parapsilosis (CP) isolates were inhibited by RZF at ≤2 µg/mL. Resistance to fluconazole was detected among 10.7% of CG, 10.2% of CP, 1.9% of CT, and 0.7% of CA. The activity of RZF against these 6 Candida spp. was similar to that of the other echinocandins, the vast majority of which were susceptible/wild type (WT) using CBP/ECV. Fluconazole and other triazoles displayed good activity against CNEO whereas echinocandins, including RZF, displayed limited activity against CNEO isolates (MIC90 >8 µg/mL). Echinocandins displayed good activity against ASF and AFL, and RZF activity was similar to that of anidulafungin, caspofungin, and micafungin. All isolates displayed WT MIC values for the mold-active azoles. CONCLUSION: Rezafungin was as active as other echinocandins against common fungal organisms recovered from invasive fungal infections. The extended half-life and stability of rezafungin is very desirable for prevention and treatment, especially in patients who could be discharged on outpatient therapy. [Image: see text] DISCLOSURES: M. A. Pfaller, Cidara Pharmaceuticals: Research Contractor, Research support. S. A. Messer, Cidara Pharmaceuticals: Research Contractor, Research support. P. R. Rhomberg, Cidara Pharmaceuticals: Research Contractor, Research support. B. A. Schaefer, Cidara Pharmaceuticals: Research Contractor, Research support. M. Castanheira, Cidara Pharmaceuticals: Research Contractor, Research support.
format Online
Article
Text
id pubmed-6253711
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62537112018-11-28 2400. Activity of a Long-Acting Echinocandin, Rezafungin, Tested Against Invasive Fungal Isolates Collected Worldwide Pfaller, Michael A Messer, Shawn A Rhomberg, Paul R Schaefer, Beth A Castanheira, Mariana Open Forum Infect Dis Abstracts BACKGROUND: Echinocandins are important agents for treating invasive fungal infections. We evaluated the activity of rezafungin (RZF; previously CD101), an echinocandin with extended half-life, and comparators using CLSI broth microdilution methods against 719 invasive fungal isolates collected worldwide during 2017. METHODS: Susceptibility tests were conducted on 616 Candida spp. (6 species), 25 C. neoformans (CNEO), 18 A. flavus (AFL), and 60 A. fumigatus (AFU) for RZF, anidulafungin, caspofungin, micafungin, and azoles. CLSI clinical breakpoint (CBP) and epidemiological cutoff value (ECV) interpretive criteria were applied. RESULTS: RZF inhibited 100.0% of C. albicans (CA) isolates, 96.3% of C. tropicalis (CT), 93.4% of C. glabrata (CG), 100.0% of C. krusei, and 100.0% of C. dubliniensis at ≤0.12 µg/mL. All but 2 (116/118 [98.3%]) C. parapsilosis (CP) isolates were inhibited by RZF at ≤2 µg/mL. Resistance to fluconazole was detected among 10.7% of CG, 10.2% of CP, 1.9% of CT, and 0.7% of CA. The activity of RZF against these 6 Candida spp. was similar to that of the other echinocandins, the vast majority of which were susceptible/wild type (WT) using CBP/ECV. Fluconazole and other triazoles displayed good activity against CNEO whereas echinocandins, including RZF, displayed limited activity against CNEO isolates (MIC90 >8 µg/mL). Echinocandins displayed good activity against ASF and AFL, and RZF activity was similar to that of anidulafungin, caspofungin, and micafungin. All isolates displayed WT MIC values for the mold-active azoles. CONCLUSION: Rezafungin was as active as other echinocandins against common fungal organisms recovered from invasive fungal infections. The extended half-life and stability of rezafungin is very desirable for prevention and treatment, especially in patients who could be discharged on outpatient therapy. [Image: see text] DISCLOSURES: M. A. Pfaller, Cidara Pharmaceuticals: Research Contractor, Research support. S. A. Messer, Cidara Pharmaceuticals: Research Contractor, Research support. P. R. Rhomberg, Cidara Pharmaceuticals: Research Contractor, Research support. B. A. Schaefer, Cidara Pharmaceuticals: Research Contractor, Research support. M. Castanheira, Cidara Pharmaceuticals: Research Contractor, Research support. Oxford University Press 2018-11-26 /pmc/articles/PMC6253711/ http://dx.doi.org/10.1093/ofid/ofy210.2053 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Pfaller, Michael A
Messer, Shawn A
Rhomberg, Paul R
Schaefer, Beth A
Castanheira, Mariana
2400. Activity of a Long-Acting Echinocandin, Rezafungin, Tested Against Invasive Fungal Isolates Collected Worldwide
title 2400. Activity of a Long-Acting Echinocandin, Rezafungin, Tested Against Invasive Fungal Isolates Collected Worldwide
title_full 2400. Activity of a Long-Acting Echinocandin, Rezafungin, Tested Against Invasive Fungal Isolates Collected Worldwide
title_fullStr 2400. Activity of a Long-Acting Echinocandin, Rezafungin, Tested Against Invasive Fungal Isolates Collected Worldwide
title_full_unstemmed 2400. Activity of a Long-Acting Echinocandin, Rezafungin, Tested Against Invasive Fungal Isolates Collected Worldwide
title_short 2400. Activity of a Long-Acting Echinocandin, Rezafungin, Tested Against Invasive Fungal Isolates Collected Worldwide
title_sort 2400. activity of a long-acting echinocandin, rezafungin, tested against invasive fungal isolates collected worldwide
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253711/
http://dx.doi.org/10.1093/ofid/ofy210.2053
work_keys_str_mv AT pfallermichaela 2400activityofalongactingechinocandinrezafungintestedagainstinvasivefungalisolatescollectedworldwide
AT messershawna 2400activityofalongactingechinocandinrezafungintestedagainstinvasivefungalisolatescollectedworldwide
AT rhombergpaulr 2400activityofalongactingechinocandinrezafungintestedagainstinvasivefungalisolatescollectedworldwide
AT schaeferbetha 2400activityofalongactingechinocandinrezafungintestedagainstinvasivefungalisolatescollectedworldwide
AT castanheiramariana 2400activityofalongactingechinocandinrezafungintestedagainstinvasivefungalisolatescollectedworldwide